Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04044859 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorPrimary completion date changed from estimate of Dec 23, 2026 to Apr 15, 2026Eligibility criteria expanded, about 17 words · Site details revised at 1 of 17 sitesShow 2 more changesShow less
Eligibility criteria expanded, about 17 words
Site details revised at 1 of 17 sites
MinorRe-verified, no change to tracked fieldsv27
NotablePrimary completion pushed from Apr 23, 2026 to Dec 23, 2026v26
NotableLead sponsor: Adaptimmune to USWM CT, LLCPrimary completion date: Dec 23, 2025 to Apr 23, 2026 · Collaborators shortened, about 2 wordsv25Show 2 more changesShow less
Primary completion date: Dec 23, 2025 to Apr 23, 2026
MinorTrial status: Recruiting to Active, Not RecruitingStudy sites: 22 to 17v24Show 1 more changeShow less
Study sites: 22 to 17
Show 22 earlier versionsHide 22 earlier versions
NotablePrimary completion date: Sep 30, 2023 to Dec 23, 2025v23
MinorSite details revised at 1 of 22 sitesv22
NotablePrimary endpoints revised (2)Enrollment target: 90 to 120 · Study sites: 21 to 22 · Interventions: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks (Genetic) to Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks… · 2 morev21Show 5 more changesShow less
Enrollment target: 90 to 120
Study sites: 21 to 22
Interventions: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks (Genetic) to Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks…
Secondary endpoints: details revised at 4 of 7 entries
NotableEnrollment target: 60 to 90Primary endpoints revised (2) · Interventions: Autologous genetically modified ADP-A2M4CD8 cells (Genetic) to Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks (Genetic) · Secondary endpoints: details revised at 4 of 7 entries · 4 morev17Show 7 more changesShow less
Primary endpoints revised (2)
Interventions: Autologous genetically modified ADP-A2M4CD8 cells (Genetic) to Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks (Genetic)
Secondary endpoints: details revised at 4 of 7 entries
MinorEligibility criteria expanded, about 21 wordsSite contacts updated at 1 of 20 sites · Collaborators expanded, about 2 wordsv16Show 2 more changesShow less
NotablePrimary completion date: Apr 30, 2022 to Sep 30, 2023Enrollment target: 45 to 60 · Study sites: 19 to 20 · Eligibility criteria expanded, about 3 wordsv15Show 3 more changesShow less
NotableEnrollment target: 30 to 45Primary completion date: Jan 14, 2021 to Apr 30, 2022 · Start date: Apr 30, 2018 to Aug 20, 2019 · Study sites: 17 to 19 · 2 morev12Show 5 more changesShow less
Primary completion date: Jan 14, 2021 to Apr 30, 2022
MinorCompletion date: Jan 14, 2021 to Jan 14, 2036Start date: Jul 10, 2019 to Apr 30, 2018 · Eligibility criteria expanded, about 8 words · Study sites revised (16)v9Show 3 more changesShow less
NotableTrial status: Not Yet Recruiting to RecruitingStart date changed from estimate of Sep 30, 2019 to Jul 10, 2019 · Site details revised at 7 of 7 sitesv4Show 2 more changesShow less
Start date changed from estimate of Sep 30, 2019 to Jul 10, 2019
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.